14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KURA vs AKRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AKRO Captures Overall Composite Edge (60.0 BUY vs 72.4 BUY), While KURA Leads 4–1 on Growth & Valuation Pillars
AKRO Overall Winner
6-Pillar Tally: KURA 4 – 1 AKRO (1 Tie)
Matrix Metrics: KURA 2 – 5 AKRO
As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Kura Oncology, Inc. (KURA) on higher Unified Composite conviction (60.0/100 BUY vs. 72.4/100 BUY) after splitting the core matrix 5–2 (led by Profitability & Quality), while KURA wins 4–1 across the 6-pillar growth and valuation breakdown. KURA trades at $6.91 (N/M Forward P/E, -394.3% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (72.4/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -394.3% operating margin) and revenue trajectory (+0.0% vs. +10.1% YoY).
Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KURA vs AKRO. Trailing 12-month operating profitability (KURA -394.3% vs AKRO 0.0%) and valuation multiples (KURA N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KURA vs AKRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Kura Oncology, Inc. (KURA) on higher Unified Composite conviction (60.0/100 BUY vs. 72.4/100 BUY) after splitting the core matrix 5–2 (led by Profitability & Quality), while KURA wins 4–1 across the 6-pillar growth and valuation breakdown. KURA trades at $6.91 (N/M Forward P/E, -394.3% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (72.4/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -394.3% operating margin) and revenue trajectory (+0.0% vs. +10.1% YoY). Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KURA leads the Growth & Scale pillar: KURA posts +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KURA generates $79M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, KURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.
KURA screens cheaper on headline valuation multiples. KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.1x EV/Revenue (-112.4% FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KURA (-224.8% ROE) versus AKRO (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, KURA carries 120.5% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 107% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.